WO2022240165A1 - Pharmaceutical composition for preventing or treating age-related macular degeneration - Google Patents
Pharmaceutical composition for preventing or treating age-related macular degeneration Download PDFInfo
- Publication number
- WO2022240165A1 WO2022240165A1 PCT/KR2022/006706 KR2022006706W WO2022240165A1 WO 2022240165 A1 WO2022240165 A1 WO 2022240165A1 KR 2022006706 W KR2022006706 W KR 2022006706W WO 2022240165 A1 WO2022240165 A1 WO 2022240165A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- macular degeneration
- age
- related macular
- formula
- pharmaceutical composition
- Prior art date
Links
- 206010064930 age-related macular degeneration Diseases 0.000 title claims abstract description 86
- 208000002780 macular degeneration Diseases 0.000 title claims abstract description 74
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 31
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims abstract description 36
- 239000000203 mixture Substances 0.000 claims abstract description 33
- 230000002207 retinal effect Effects 0.000 claims abstract description 32
- 235000013305 food Nutrition 0.000 claims abstract description 20
- 235000005152 nicotinamide Nutrition 0.000 claims abstract description 18
- 239000011570 nicotinamide Substances 0.000 claims abstract description 18
- 229960003966 nicotinamide Drugs 0.000 claims abstract description 18
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 238000011282 treatment Methods 0.000 claims description 32
- 208000008069 Geographic Atrophy Diseases 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 206010003694 Atrophy Diseases 0.000 claims description 10
- 230000037444 atrophy Effects 0.000 claims description 10
- 230000005856 abnormality Effects 0.000 claims description 6
- 210000000981 epithelium Anatomy 0.000 claims description 6
- 150000005480 nicotinamides Chemical class 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 5
- 210000002919 epithelial cell Anatomy 0.000 abstract description 25
- 230000000694 effects Effects 0.000 abstract description 13
- 230000007850 degeneration Effects 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 201000004569 Blindness Diseases 0.000 abstract description 4
- 208000011325 dry age related macular degeneration Diseases 0.000 abstract description 3
- 238000010171 animal model Methods 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 18
- 239000000126 substance Substances 0.000 description 18
- 239000011697 sodium iodate Substances 0.000 description 14
- 235000015281 sodium iodate Nutrition 0.000 description 14
- 241000713666 Lentivirus Species 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- NALMPLUMOWIVJC-UHFFFAOYSA-N n,n,4-trimethylbenzeneamine oxide Chemical compound CC1=CC=C([N+](C)(C)[O-])C=C1 NALMPLUMOWIVJC-UHFFFAOYSA-N 0.000 description 10
- 210000001525 retina Anatomy 0.000 description 10
- 229940032753 sodium iodate Drugs 0.000 description 10
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 7
- 208000012101 immune-mediated necrotizing myopathy Diseases 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000012790 confirmation Methods 0.000 description 6
- 241000872931 Myoporum sandwicense Species 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000001508 eye Anatomy 0.000 description 5
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 235000005985 organic acids Nutrition 0.000 description 4
- 210000000608 photoreceptor cell Anatomy 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000004087 cornea Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 229960003512 nicotinic acid Drugs 0.000 description 3
- -1 optical isomers Chemical class 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 2
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 208000002141 Pellagra Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 206010047571 Visual impairment Diseases 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000002137 anti-vascular effect Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 210000000944 nerve tissue Anatomy 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 208000029257 vision disease Diseases 0.000 description 2
- 230000004304 visual acuity Effects 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100023387 Endoribonuclease Dicer Human genes 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101000907904 Homo sapiens Endoribonuclease Dicer Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010029400 Nicotinic acid deficiency Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005157 neural retina Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000008154 viscoelastic solution Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
Definitions
- the present invention relates to a pharmaceutical composition for preventing or treating age-related macular degeneration.
- Age-related macular degeneration is a disease caused by various changes in the macular area of the retina with aging. The incidence increases with age, and it is known that there are about 200 million patients worldwide as the number one cause of adult blindness in developed countries. Therefore, as the elderly population increases in Korea, the incidence is expected to increase further.
- the macula refers to the central part of the nerve tissue called the retina, and is responsible for central vision because photoreceptor cells that respond to light stimulation are concentrated.
- Age-related macular degeneration is a loss of these macular photoreceptor cells as aging progresses and causes visual impairment, and can be divided into 1 wet or exudative form and 2 dry or non-exudative form.
- neovascular, exudative form when choroidal neovascularization grows under the retina, it is treated by intraocular injection of anti-vascular endothelial growth factor (VEGF) monoclonal antibody.
- VEGF anti-vascular endothelial growth factor
- the dry (atrophic) form accounts for most of AMD and refers to cases in which lesions such as drusen, pigmentary abnormalities, or atrophy of the retinal epithelium occur in the retina. Progressive macular degeneration during dryness is called geographic atrophy (GA), and currently there is no treatment, which is the biggest challenge in age-related macular degeneration.
- GA geographic atrophy
- the present invention was conceived to solve the above problems, and the present invention relates to a pharmaceutical composition for preventing or treating age-related macular degeneration.
- the pharmaceutical composition of the present invention is expected to be widely used in the medical field because it exhibited a very remarkable therapeutic effect not only in wet but also in dry age-related macular degeneration for which there is no treatment.
- An object of the present invention is to provide a pharmaceutical composition for preventing or treating age-related macular degeneration.
- ASD Age-related macular degeneration
- AMD is a disease caused by various changes in the macular region of the retina with aging.
- the incidence increases with age, and it is known that there are about 200 million patients worldwide as the number one cause of adult blindness in developed countries. Therefore, as the elderly population increases in Korea, the incidence is expected to increase further.
- the macula refers to the central part of the nerve tissue called the retina, and is responsible for central vision because photoreceptor cells that respond to light stimulation are concentrated.
- Age-related macular degeneration is a loss of these macular photoreceptor cells as aging progresses and causes visual impairment, and can be divided into 1 wet or exudative form and 2 dry or non-exudative form.
- neovascular, exudative form when choroidal neovascularization grows under the retina, it is treated by intraocular injection of anti-vascular endothelial growth factor (VEGF) monoclonal antibody.
- VEGF anti-vascular endothelial growth factor
- the dry (atrophic) form accounts for most of AMD and refers to cases in which lesions such as drusen, pigmentary abnormalities, or atrophy of the retinal epithelium occur in the retina. Progressive macular degeneration during dryness is called geographic atrophy (GA), and currently there is no treatment, which is the biggest challenge in age-related macular degeneration.
- GA geographic atrophy
- nicotinamide is a kind of vitamin B complex, which coexists with nicotinic acid in plants and is widely distributed, and exists as a component of NAD + or NADP +, which is a redox coenzyme, in vivo . Also referred to as niacin in a narrow sense.
- Nicotinamide also known as niacinamide, is a form of vitamin B3 found in foods and used as a dietary supplement and drug. As a supplement, it is also used orally to prevent and treat pellagra (a disease caused by niacin deficiency).
- the nicotinamide is represented by Formula 1 below.
- “derivative of nicotinamide” means a compound obtained by changing a part of the molecular structure of nicotinamide represented by Formula 1 above.
- the nicotinamide derivative is represented by Formula 2 or Formula 3 below, but is not limited thereto.
- pharmaceutical composition means a composition administered for a specific purpose.
- the pharmaceutical composition of the present invention is to prevent or treat age-related macular degeneration, and may include a compound involved in this and a pharmaceutically acceptable carrier, excipient or diluent.
- the pharmaceutical composition according to the present invention contains 0.1 to 50% by weight of the active ingredient of the present invention based on the total weight of the composition.
- Carriers, excipients and diluents that may be included in the composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginates, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.
- the pharmaceutical composition for the prevention and treatment of age-related macular degeneration of the present invention is preferably any one compound selected from Formulas 1 to 3, or pharmaceutically acceptable salts, optical isomers, hydrates and solvates thereof. It includes a compound selected from.
- the pharmaceutically acceptable salt should have low toxicity to the human body and should not adversely affect the biological activity and physicochemical properties of the parent compound.
- a pharmaceutically acceptable salt may be an acid addition salt of a pharmaceutically acceptable free acid and a base compound, but is not limited thereto.
- Preferred salt forms of the compounds according to the present invention include salts with inorganic acids or organic acids.
- the inorganic acid may be hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, bromic acid, or the like.
- organic acids include acetic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, fumaric acid, maleic acid, malonic acid, phthalic acid, succinic acid, lactic acid, citric acid, citric acid, gluconic acid, tartaric acid, salicylic acid, malic acid, Oxalic acid, benzoic acid, embonic acid, aspartic acid, glutamic acid and the like can be used.
- Organic bases that can be used in preparing the organic base addition salt include tris(hydroxymethyl)methylamine and dicyclohexylamine.
- Amino acids that can be used in preparing amino acid addition salts are natural amino acids such as alanine and glycine. It will be apparent to those skilled in the art that acids or bases other than the inorganic acids, organic acids, organic bases, and amino acids exemplified above may be used.
- the salt may be prepared by a conventional method.
- the compounds according to the present invention may have an asymmetric carbon center, they may exist as R or S isomers or racemic compounds, and all optical isomers and mixtures thereof may be included in the scope of the present invention.
- prevention may include without limitation any action that blocks symptoms caused by age-related macular degeneration by using the pharmaceutical composition of the present invention, or suppresses or delays the symptoms.
- treatment may include without limitation any action that improves or benefits symptoms caused by age-related macular degeneration by using the pharmaceutical composition of the present invention.
- the pharmaceutical composition may be in the form of capsules, tablets, granules, injections, ointments, powders or beverages, preferably animals, more preferably mammals, and most preferably humans. It can be characterized as target.
- administration means introducing the composition of the present invention to a patient by any suitable method, and the administration route of the composition of the present invention is through any general route as long as it can reach the target tissue.
- oral administration intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, intranasal administration, intrapulmonary administration, intrarectal administration, intracavitary administration, intraperitoneal administration, intrathecal administration, or intraocular administration It may be made in the form, and the intraocular administration is more specifically intravitreal injection, retrobulbar injection, subconjunctival injection, sub-tenon injection, or It may be made in the form of intraocular drops, but is not limited thereto.
- the effective amount is the type of disease, the severity of the disease, the type and amount of the active ingredient and other ingredients contained in the composition, the type of formulation and the patient's age, weight, general health condition, sex and diet, administration time, administration route And it can be adjusted according to various factors including the secretion rate of the composition, the treatment period, and drugs used simultaneously.
- the therapeutic pharmaceutical composition can be administered to the body in an amount of 50 ml to 500 ml once, and in the case of a compound, 0.1 ng/kg-10 mg/kg, and in the case of a monoclonal antibody, 0.1 ng/kg-10 mg /kg may be administered.
- the administration interval may be 1 to 12 times a day, and in the case of administration 12 times a day, it may be administered once every 2 hours.
- the pharmaceutical composition of the present invention can be administered alone or with other treatments known in the art for the desired treatment, such as chemotherapy, radiation, and surgery.
- the pharmaceutical composition of the present invention may be administered in combination with other therapies designed to enhance the immune response, such as adjuvants or cytokines (or nucleic acids encoding cytokines) well known in the art.
- Other standard delivery methods may also be used, such as biolistic delivery or ex vivo treatment.
- antigen presenting cells for example, antigen presenting cells (APCs), dendritic cells, peripheral blood mononuclear cells, or bone marrow cells may be obtained from a patient or a suitable donor, activated in vitro with the present pharmaceutical composition, and then administered to the patient. have.
- APCs antigen presenting cells
- dendritic cells dendritic cells
- peripheral blood mononuclear cells or bone marrow cells
- bone marrow cells may be obtained from a patient or a suitable donor, activated in vitro with the present pharmaceutical composition, and then administered to the patient. have.
- "food composition” is used in various ways to prevent or improve the indications aimed at in the present invention
- the food composition containing the composition of the present invention as an active ingredient is various foods, such as For example, it can be manufactured in the form of beverages, gum, tea, vitamin complexes, powders, granules, tablets, capsules, confectionery, rice cakes, and bread. Since the food composition of the present invention is improved from existing food intakes with little toxicity and side effects, it can be safely used even when taken for a long period of time for preventive purposes.
- the amount may be added in an amount of 0.1 to 100% of the total weight.
- natural carbohydrates include monosaccharides such as glucose, disaccharides such as fructose, polysaccharides such as sucrose, and common sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. can do.
- the flavoring agent examples include natural flavoring agents (thaumatin, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.).
- the food composition of is various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, Stabilizers, preservatives, glycerin, alcohol, carbonation agents used in carbonated beverages, etc. These components may be used independently or in combination
- the ratio of these additives is usually per 100 parts by weight of the composition of the present invention It is generally selected from the range of 0.1 to 100 parts by weight, but is not limited thereto.
- a pharmaceutical composition for preventing or treating age-related macular degeneration comprising nicotinamide or a derivative thereof as an active ingredient, wherein the age-related macular degeneration is dry or wet, age-related macular degeneration
- a pharmaceutical composition for prevention or treatment wherein the age-related macular degeneration is accompanied by drusen, pigmentary abnormality, or atrophy of the retinal epithelium. It provides, and the atrophy provides a pharmaceutical composition for preventing or treating age-related macular degeneration, which is a geographic atrophy.
- the nicotinamide is represented by Formula 1 below, and the nicotinamide derivative is represented by Formula 2 or Formula 3 below.
- a food composition for preventing or improving age-related macular degeneration comprising nicotinamide or a derivative thereof as an active ingredient, wherein the age-related macular degeneration is dry or wet
- a food composition for prevention or improvement wherein the age-related macular degeneration is accompanied by drusen, pigmentary abnormality, or atrophy of the retinal epithelium.
- a food composition for preventing or improving age-related macular degeneration It provides, and the atrophy provides a food composition for preventing or improving age-related macular degeneration, which is a geographic atrophy.
- the nicotinamide is represented by Formula 1 below, and the nicotinamide derivative is represented by Formula 2 or Formula 3 below.
- a pharmaceutical composition and a food composition containing nicotinamide or a derivative thereof according to the present invention as an active ingredient have an effect of significantly recovering structurally and functionally the degeneration of retinal epithelial cells in age-related macular degeneration.
- FIG. 2 is a result of structurally confirming the treatment effect of age-related macular degeneration in retinal epithelial cells according to the candidate substance administered in an age-related macular degeneration animal model prepared using a lentivirus according to an embodiment of the present invention.
- 3 is a result of structurally confirming the treatment effect of age-related macular degeneration in retinal epithelial cells according to the candidate substance administered to the age-related macular degeneration animal model prepared using sodium iodate according to an embodiment of the present invention.
- 4a to 4d are the results of functionally confirming the treatment effect of age-related macular degeneration in retinal epithelial cells according to the candidate substance administered in the age-related macular degeneration animal model prepared using sodium iodate according to an embodiment of the present invention. .
- An age-related macular degeneration animal model realizing geographic atrophy was prepared, and the compounds of Table 1 were administered as candidates for treatment of age-related macular degeneration.
- the control group to which the compound was not administered showed geographic atrophy of typical age-related macular degeneration, but in the case of administration of the compound of Table 1, the order of Formula 2 (NMN) ⁇ Formula 3 (NR) > Formula 1 (NAM) It was confirmed that structural or functional recovery of retinal epithelial cell degeneration was remarkable.
- Age-related macular degeneration animal model is the same as the previously known method (Kaneko, H. et al. DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. Nature 471, 325-330, doi:10.1038/nature09830. 2011.) performed.
- This method is a method of generating geographic atrophy by Alu RNA accumulated in retinal pigment epithelium (RPE).
- GFP green fluorescence protein
- Alu RNA expressing lentival vector Alu RNA expressing lentival vector
- WPI microliter syringe
- GC 0.8 X 10 8 genome copy
- a small incision is made with a 30 gauge injection needle at a location 1 mm away from the limbus, and a 33 gauge blunt needle of a microliter syringe is inserted through the incision, and a point where resistance is felt (subretinal space) ), the needle was approached.
- antibiotic ointment was applied to the ocular surface.
- the experiments were performed on a heating pad to maintain the body temperature of the mice. After 2 weeks, eye samples were obtained from the mice and RPE whole mount immunostatining was performed.
- an animal model for age-related macular degeneration using a chemical method was additionally prepared.
- 8-10 week-old C57BL/6 mice were prepared in the same manner as above, and sodium iodate (NAIO 3 ) was injected intravascularly through the tail vein at a concentration of 20 mg/Kg.
- an electroretinogram (ERG) was performed, and eye samples were obtained from mice, and RPE whole mount immunostatining was performed.
- Candidates for the treatment of age-related macular degeneration used the compounds in Table 1 below, and from 3 days before administration of lentivirus or sodium iodate for preparing the above two types of animal models to the day of obtaining eye samples, 1000 mg/Kg/ It was intraperitoneal injection every day at the concentration of day.
- Example 2 Confirmation of age-related macular degeneration treatment effect of candidate substance through confirmation of retinal epithelial cell morphology
- Retinal cell staining for confirmation of retinal epithelial cell morphology was performed in the following order.
- the obtained eye sample was fixed with 1% paraformaldehyde for 1 hour, and after removing the muscle, cornea, lens, and neural retina, Sclera
- the /Choroid/RPE complex was radially sectioned into eight pieces.
- Each tissue section was prepared in Phosphate buffered saline containing 5% bovine serum albumin, 2% NDS (normal donkey serum), and 0.3% TritonTM X-100. -buffered saline) solution for 1 hour after blocking, washing, and overnight reaction with anti-ZO-1 antibody at 4°C (overnight incubation). Thereafter, the cells were washed three times, reacted with the secondary antibody at room temperature for 1 hour, washed again, and the tissues were smeared on slides and then embedded. This was observed with a fluorescence microscope.
- Example 2-1 Confirmation of effect in animal models using lentivirus
- FIG. 1 the result of confirming whether the age-related macular degeneration animal model prepared by the method using the lentivirus in Example 1 was prepared as intended is shown in FIG. 1.
- Figure 1 when transduction of lentivirus expressing GFP as a control, no structural change occurred in normal retinal epithelial cells (left), but when transduction of lentivirus expressing Alu RNA, retinal epithelial cells degenerated As a result, the retinal epithelial cells increased in size and became irregular in shape (right). Through this, it was confirmed that the target age-related macular degeneration animal model was well prepared by the method using the lentivirus.
- the control group (Alu RNA) to which the compound was not administered showed typical geographic atrophy of age-related macular degeneration.
- Formula 1 was administered (Alu RNA + NAM treatment)
- an increase in the size of retinal epithelial cells was observed, but the size of retinal epithelial cells was significantly smaller than that of the control group (Alu RNA).
- Example 2-2 Confirmation of effect in animal models using sodium iodate
- Example 3 Confirmation of age-related macular degeneration treatment effect of candidate substance through visual acuity measurement in objective view
- the present invention relates to a pharmaceutical composition for preventing or treating age-related macular degeneration.
- Age-related macular degeneration is a disease caused by various changes in the macular area of the retina with aging. The incidence increases with age, and it is known that there are about 200 million patients worldwide as the number one cause of adult blindness in developed countries. However, progressive macular degeneration, which accounts for most of AMD, is called geographic atrophy (GA), and currently there is no treatment, which is the biggest challenge in age-related macular degeneration.
- GA geographic atrophy
- the pharmaceutical composition of the present invention is expected to be widely used in the medical field because it exhibited a very remarkable therapeutic effect not only in wet but also in dry age-related macular degeneration for which there is no treatment.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a pharmaceutical composition for preventing or treating age-related macular degeneration. Age-related macular degeneration is the number one cause of adult blindness in developed countries. Dry age-related macular degeneration, which is the more common type of age-related macular degeneration, is currently the most serious problem since there is no cure for the disease. The pharmaceutical composition and a food composition according to the present invention comprising nicotinamide or a derivative thereof as an active ingredient have an effect of significantly relieving, structurally and functionally, degeneration of retinal epithelial cells in age-related macular degeneration, and thus are expected to be widely used in the medical field.
Description
본 발명은 노인성 황반변성의 예방 또는 치료를 위한 약학 조성물에 관한 것이다.The present invention relates to a pharmaceutical composition for preventing or treating age-related macular degeneration.
노인성 황반변성(age-related macular degeneration: AMD)은 나이가 들면서 망막의 황반부에 여러 가지 변화가 동반되어 생기는 질병이다. 나이가 증가함에 따라 발생율이 증가하며, 선진국에서는 성인 실명 원인 1위 질환으로 전세계적으로 약 2억명 정도의 환자가 있는 것으로 알려져 있다. 따라서 우리나라에서도 앞으로 노인 인구가 증가함에 따라서 그 발생 빈도는 더욱 증가하리라 예상된다. 황반은 망막이라고 하는 신경 조직의 중심 부위를 말하는데, 빛 자극에 반응하는 광수용체 세포가 밀집되어 있어 중심 시력을 담당한다. 노인성 황반변성은 노화가 진행됨에 따라 이러한 황반부 광수용체 세포가 소실되어 시력 장애를 일으키는 것으로, ① 습성 또는 삼출성 형태와 ② 건성 또는 비삼출성 형태로 나눌 수 있다. Age-related macular degeneration (AMD) is a disease caused by various changes in the macular area of the retina with aging. The incidence increases with age, and it is known that there are about 200 million patients worldwide as the number one cause of adult blindness in developed countries. Therefore, as the elderly population increases in Korea, the incidence is expected to increase further. The macula refers to the central part of the nerve tissue called the retina, and is responsible for central vision because photoreceptor cells that respond to light stimulation are concentrated. Age-related macular degeneration is a loss of these macular photoreceptor cells as aging progresses and causes visual impairment, and can be divided into ① wet or exudative form and ② dry or non-exudative form.
습성(wet=neovascular, exudative) 형태는 망막 밑에 맥락막 신생혈관이 자라는 경우로 항혈관내피성장인자 항체(Anti-vascular endothelial growth factor (VEGF) monoclonal antibody)를 안구내 주사하는 방법으로 치료한다. 건성(dry=atrophic) 형태는 AMD의 대부분을 차지하며 망막에 드루젠(drusen)이나 색소이상(pigmentary abnormality), 또는 망막상피의 위축(atrophy)과 같은 병변이 생긴 경우를 말한다. 건성 중 진행성 황반변성을 지도형 위축(geographic atrophy: GA)라고 하는데, 현재로서는 치료법이 전무하여 노인성 황반변성의 최대 난제인 실정이다.In the wet = neovascular, exudative form, when choroidal neovascularization grows under the retina, it is treated by intraocular injection of anti-vascular endothelial growth factor (VEGF) monoclonal antibody. The dry (atrophic) form accounts for most of AMD and refers to cases in which lesions such as drusen, pigmentary abnormalities, or atrophy of the retinal epithelium occur in the retina. Progressive macular degeneration during dryness is called geographic atrophy (GA), and currently there is no treatment, which is the biggest challenge in age-related macular degeneration.
따라서 본 발명은 상기와 같은 문제의 해결을 위해 고안된 것으로, 본 발명은 노인성 황반변성의 예방 또는 치료를 위한 약학 조성물에 관한 것이다. 본 발명의 약학조성물은 습성뿐만 아니라 치료법이 전무한 건성의 노인성 황반변성에서도 매우 현저한 치료 효과를 발휘하였으므로, 의료 분야에서 크게 이용될 수 있을 것으로 기대된다.Therefore, the present invention was conceived to solve the above problems, and the present invention relates to a pharmaceutical composition for preventing or treating age-related macular degeneration. The pharmaceutical composition of the present invention is expected to be widely used in the medical field because it exhibited a very remarkable therapeutic effect not only in wet but also in dry age-related macular degeneration for which there is no treatment.
본 발명의 목적은 노인성 황반변성의 예방 또는 치료를 위한 약학조성물을 제공하는 것이다. An object of the present invention is to provide a pharmaceutical composition for preventing or treating age-related macular degeneration.
그러나 본 발명이 이루고자 하는 기술적 과제는 이상에서 언급한 과제에 제한되지 않으며, 언급되지 않은 또 다른 과제들은 아래의 기재로부터 당업계에서 통상의 지식을 가진 자에게 명확하게 이해될 수 있을 것이다.However, the technical problem to be achieved by the present invention is not limited to the above-mentioned problems, and other problems not mentioned will be clearly understood by those skilled in the art from the following description.
이하, 본원에 기재된 다양한 구체예가 도면을 참조로 기재된다. 하기 설명에서, 본 발명의 완전한 이해를 위해서, 다양한 특이적 상세사항, 예컨대, 특이적 형태, 조성물 및 공정 등이 기재되어 있다. 그러나, 특정의 구체예는 이들 특이적 상세 사항 중 하나 이상 없이, 또는 다른 공지된 방법 및 형태와 함께 실행될 수 있다. 다른 예에서, 공지된 공정 및 제조 기술은 본 발명을 불필요하게 모호하게 하지 않게 하기 위해서, 특정의 상세사항으로 기재되지 않는다. "한 가지 구체예" 또는 "구체예"에 대한 본 명세서 전체를 통한 참조는 구체예와 결부되어 기재된 특별한 특징, 형태, 조성 또는 특성이 본 발명의 하나 이상의 구체예에 포함됨을 의미한다. 따라서, 본 명세서 전체에 걸친 다양한 위치에서 표현된 "한 가지 구체예에서" 또는 "구체예"의 상황은 반드시 본 발명의 동일한 구체예를 나타내지는 않는다. 추가로, 특별한 특징, 형태, 조성, 또는 특성은 하나 이상의 구체예에서 어떠한 적합한 방법으로 조합될 수 있다.Hereinafter, various embodiments described herein are described with reference to the drawings. In the following description, numerous specific details are set forth, such as specific forms, compositions and processes, etc., in order to provide a thorough understanding of the present invention. However, certain embodiments may be practiced without one or more of these specific details, or with other known methods and forms. In other instances, well known processes and manufacturing techniques have not been described in specific detail in order not to unnecessarily obscure the present invention. Reference throughout this specification to “one embodiment” or “an embodiment” means that a particular feature, form, composition or characteristic described in connection with the embodiment is included in one or more embodiments of the invention. Thus, the appearances of "in one embodiment" or "an embodiment" in various places throughout this specification do not necessarily refer to the same embodiment of the invention. Additionally, particular features, forms, compositions, or properties may be combined in one or more embodiments in any suitable way.
명세서에서 특별한 정의가 없으면 본 명세서에 사용된 모든 과학적 및 기술적인 용어는 본 발명이 속하는 기술분야에서 당업자에 의하여 통상적으로 이해되는 것과 동일한 의미를 가진다.Unless otherwise defined in the specification, all scientific and technical terms used herein have the same meaning as commonly understood by a person skilled in the art to which the present invention belongs.
본 발명의 일 구체예에서 “노인성 황반변성(Age-related macular degeneration: AMD)”이란, 나이가 들면서 망막의 황반부에 여러 가지 변화가 동반되어 생기는 질병이다. 나이가 증가함에 따라 발생율이 증가하며, 선진국에서는 성인 실명 원인 1위 질환으로 전세계적으로 약 2억명 정도의 환자가 있는 것으로 알려져 있다. 따라서 우리나라에서도 앞으로 노인 인구가 증가함에 따라서 그 발생 빈도는 더욱 증가하리라 예상된다. 황반은 망막이라고 하는 신경 조직의 중심 부위를 말하는데, 빛 자극에 반응하는 광수용체 세포가 밀집되어 있어 중심 시력을 담당한다. 노인성 황반변성은 노화가 진행됨에 따라 이러한 황반부 광수용체 세포가 소실되어 시력 장애를 일으키는 것으로, ① 습성 또는 삼출성 형태와 ② 건성 또는 비삼출성 형태로 나눌 수 있다. In one embodiment of the present invention, “Age-related macular degeneration (AMD)” is a disease caused by various changes in the macular region of the retina with aging. The incidence increases with age, and it is known that there are about 200 million patients worldwide as the number one cause of adult blindness in developed countries. Therefore, as the elderly population increases in Korea, the incidence is expected to increase further. The macula refers to the central part of the nerve tissue called the retina, and is responsible for central vision because photoreceptor cells that respond to light stimulation are concentrated. Age-related macular degeneration is a loss of these macular photoreceptor cells as aging progresses and causes visual impairment, and can be divided into ① wet or exudative form and ② dry or non-exudative form.
습성(wet=neovascular, exudative) 형태는 망막 밑에 맥락막 신생혈관이 자라는 경우로 항혈관내피성장인자 항체(Anti-vascular endothelial growth factor (VEGF) monoclonal antibody)를 안구내 주사하는 방법으로 치료한다. 건성(dry=atrophic) 형태는 AMD의 대부분을 차지하며 망막에 드루젠(drusen)이나 색소이상(pigmentary abnormality), 또는 망막상피의 위축(atrophy)과 같은 병변이 생긴 경우를 말한다. 건성 중 진행성 황반변성을 지도형 위축(geographic atrophy: GA)라고 하는데, 현재로서는 치료법이 전무하여 노인성 황반변성의 최대 난제인 실정이다.In the wet = neovascular, exudative form, when choroidal neovascularization grows under the retina, it is treated by intraocular injection of anti-vascular endothelial growth factor (VEGF) monoclonal antibody. The dry (atrophic) form accounts for most of AMD and refers to cases in which lesions such as drusen, pigmentary abnormalities, or atrophy of the retinal epithelium occur in the retina. Progressive macular degeneration during dryness is called geographic atrophy (GA), and currently there is no treatment, which is the biggest challenge in age-related macular degeneration.
본 발명의 일 구체예에서 “니코틴아마이드(nicotinamide)”란, 비타민 B 복합체의 일종으로 식물에서는 니코틴산과 공존하여 광범위하게 분포하고, 동물의 생체 내에서 산화환원 조효소인 NAD+ 또는 NADP+의 성분으로 존재한다. 좁은 의미에서 니아신으로도 언급된다.In one embodiment of the present invention, "nicotinamide" is a kind of vitamin B complex, which coexists with nicotinic acid in plants and is widely distributed, and exists as a component of NAD + or NADP +, which is a redox coenzyme, in vivo . Also referred to as niacin in a narrow sense.
니아신아마이드로도 알려진 니코틴아마이드는 식품에서 발견되며 식이 보충제 및 약물로 사용되는 비타민 B3의 한 형태이다. 보충제로, 펠라그라(pellagra, 니아신 결핍으로 발생하는 질환)를 예방하고 치료하기 위해 경구복용으로도 사용된다.Nicotinamide, also known as niacinamide, is a form of vitamin B3 found in foods and used as a dietary supplement and drug. As a supplement, it is also used orally to prevent and treat pellagra (a disease caused by niacin deficiency).
상기 니코틴아마이드는 하기 화학식 1로 표시된다.The nicotinamide is represented by Formula 1 below.
[화학식 1][Formula 1]
본 발명의 일 구체예에서 “니코틴아마이드의 유도체”란, 상기 화학식 1로 표시되는 니코틴아마이드의 분자 구조 가운데 일부분이 변화하여 생긴 화합물을 의미한다. 본 발명에 있어서, 상기 니코틴아마이드의 유도체는 하기 화학식 2 또는 화학식 3으로 표시되는 것이나, 이제 제한되는 것은 아니다.In one embodiment of the present invention, "derivative of nicotinamide" means a compound obtained by changing a part of the molecular structure of nicotinamide represented by Formula 1 above. In the present invention, the nicotinamide derivative is represented by Formula 2 or Formula 3 below, but is not limited thereto.
[화학식 2] [Formula 2]
[화학식 3] [Formula 3]
본 발명의 일 구체예에서 “약학조성물”이란, 특정한 목적을 위해 투여되는 조성물을 의미한다. 본 발명의 목적상, 본 발명의 약학조성물은 노인성 황반변성을 예방 또는 치료하는 것이며, 이에 관여하는 화합물 및 약학적으로 허용 가능한 담체, 부형제 또는 희석제를 포함할 수 있다. 또한 본 발명에 따른 약학 조성물은 조성물 총 중량에 대하여 본 발명의 유효성분을 0.1 내지 50 중량%로 포함한다. 본 발명의 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있으나, 이에 제한되는 것은 아니다.In one embodiment of the present invention, "pharmaceutical composition" means a composition administered for a specific purpose. For the purpose of the present invention, the pharmaceutical composition of the present invention is to prevent or treat age-related macular degeneration, and may include a compound involved in this and a pharmaceutically acceptable carrier, excipient or diluent. In addition, the pharmaceutical composition according to the present invention contains 0.1 to 50% by weight of the active ingredient of the present invention based on the total weight of the composition. Carriers, excipients and diluents that may be included in the composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginates, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.
구체적으로, 본 발명의 노인성 황반변성의 예방 및 치료를 위한 약학조성물은 바람직하게는 상기 화학식 1 내지 화학식 3으로부터 선택되는 어느 하나의 화합물, 또는 이의 약학적으로 허용 가능한 염, 광학이성질체, 수화물 및 용매화물로부터 선택되는 화합물을 포함한다.Specifically, the pharmaceutical composition for the prevention and treatment of age-related macular degeneration of the present invention is preferably any one compound selected from Formulas 1 to 3, or pharmaceutically acceptable salts, optical isomers, hydrates and solvates thereof. It includes a compound selected from.
상기 약학적으로 허용 가능한 염은 인체에 독성이 낮고 모화합물의 생물학적 활성과 물리화학적 성질에 악영향을 주지 않아야 한다. 약학적으로 허용 가능한 염은 약학적으로 허용 가능한 유리산과 염기 화합물의 산부가염 등이 가능하나, 이에 제한되지는 않는다.The pharmaceutically acceptable salt should have low toxicity to the human body and should not adversely affect the biological activity and physicochemical properties of the parent compound. A pharmaceutically acceptable salt may be an acid addition salt of a pharmaceutically acceptable free acid and a base compound, but is not limited thereto.
본 발명에 따른 화합물의 바람직한 염의 형태로는 무기산 또는 유기산과의 염을 들 수 있다. 이때, 무기산은 염산, 황산, 질산, 인산, 과염소산, 브롬산 등이 사용될 수 있다. 또한, 유기산은 초산, 메탄설폰산, 에탄설폰산, p-톨루엔설폰산, 푸마린산, 말레산, 말론산, 프탈산, 숙신산, 젖산, 구연산, 시트르산, 글루콘산, 타타르산, 살리실산, 말산, 옥살산, 벤조산, 엠본산, 아스파르트산, 글루탐산 등이 사용될 수 있다. 유기염기 부가염 제조에 사용될 수 있는 유기염기는 트리스(하이드록시메틸)메틸아민, 디사이클로헥실아민 등이다. 아미노산 부가염 제조에 사용될 수 있는 아미노산은 알라닌, 글라이신 등의 천연아미노산이다. 상기 예시된 무기산, 유기산, 유기염기 및 아미노산 외에 다른 산 또는 염기가 사용될 수 있음은 당해 기술분야에서 통상의 기술을 가진 자에게 자명할 것이다. 또한 상기 염은 통상적인 방법으로 제조될 수 있다. Preferred salt forms of the compounds according to the present invention include salts with inorganic acids or organic acids. In this case, the inorganic acid may be hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, bromic acid, or the like. In addition, organic acids include acetic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, fumaric acid, maleic acid, malonic acid, phthalic acid, succinic acid, lactic acid, citric acid, citric acid, gluconic acid, tartaric acid, salicylic acid, malic acid, Oxalic acid, benzoic acid, embonic acid, aspartic acid, glutamic acid and the like can be used. Organic bases that can be used in preparing the organic base addition salt include tris(hydroxymethyl)methylamine and dicyclohexylamine. Amino acids that can be used in preparing amino acid addition salts are natural amino acids such as alanine and glycine. It will be apparent to those skilled in the art that acids or bases other than the inorganic acids, organic acids, organic bases, and amino acids exemplified above may be used. In addition, the salt may be prepared by a conventional method.
한편, 본 발명에 따른 화합물들은 비대칭 탄소 중심을 가질 수 있으므로 R 또는 S 이성질체 또는 라세믹 화합물로서 존재할 수 있으며 이들 모든 광학이성질체 및 혼합물은 본 발명의 범위에 포함될 수 있다.Meanwhile, since the compounds according to the present invention may have an asymmetric carbon center, they may exist as R or S isomers or racemic compounds, and all optical isomers and mixtures thereof may be included in the scope of the present invention.
그 외에도, 화학식 1 내지 화학식 3으로 표시되는 화합물의 수화물 또는 용매화물 형태도 본 발명의 범위에 포함될 수 있다. In addition, hydrate or solvate forms of the compounds represented by Formulas 1 to 3 may also be included in the scope of the present invention.
한편, 본 발명에서, "예방"은 본 발명의 약학조성물을 이용하여 노인성 황반변성으로 인해 발생한 증상을 차단하거나, 그 증상을 억제 또는 지연시키는 모든 행위라면 제한없이 포함할 수 있다. On the other hand, in the present invention, "prevention" may include without limitation any action that blocks symptoms caused by age-related macular degeneration by using the pharmaceutical composition of the present invention, or suppresses or delays the symptoms.
또한, 본 발명에서, "치료"는 본 발명의 약학조성물을 이용하여 노인성 황반변성으로 인해 발생한 증상이 호전되거나 이롭게 되는 모든 행위라면 제한없이 포함할 수 있다.In addition, in the present invention, "treatment" may include without limitation any action that improves or benefits symptoms caused by age-related macular degeneration by using the pharmaceutical composition of the present invention.
본 발명에서 상기 약학조성물은 캡슐, 정제, 과립, 주사제, 연고제, 분말 또는 음료 형태임을 특징으로 할 수 있으며, 상기 약학조성물은 바람직하게는 동물, 더욱 바람직하게는 포유동물, 가장 바람직하게는 인간을 대상으로 하는 것을 특징으로 할 수 있다. In the present invention, the pharmaceutical composition may be in the form of capsules, tablets, granules, injections, ointments, powders or beverages, preferably animals, more preferably mammals, and most preferably humans. It can be characterized as target.
본 발명의 일 구체예에서 “투여”란, 어떠한 적절한 방법으로 환자에게 본 발명의 조성물을 도입하는 것을 의미하며, 본 발명의 조성물의 투여경로는 목적 조직에 도달할 수 있는 한 어떠한 일반적인 경로를 통하여 투여될 수 있다. 구체적으로는 경구 투여, 복강 내 투여, 정맥 내 투여, 근육 내 투여, 피하 투여, 피내 투여, 비내 투여, 폐내 투여, 직장내 투여, 강내 투여, 복강 내 투여, 경막 내 투여, 또는 안구 내 투여의 형태로 이루어질 수 있고, 상기 안구 내 투여는 보다 구체적으로는 유리체강내 주입술(intravitreal injection), 안구 뒤 주입술(retrobulbar injection), 결막하 주입술(subconjunctival injection), 테논낭하 주입술(sub-tenon injection), 또는 안구내 점안의 형태로 이루어질 수 있으나, 이에 제한되지는 않는다. 본 발명에서 유효량은 질환의 종류, 질환의 중증도, 조성물에 함유된 유효 성분 및 다른 성분의 종류 및 함량, 제형의 종류 및 환자의 연령, 체중, 일반 건강 상태, 성별 및 식이, 투여 시간, 투여 경로 및 조성물의 분비율, 치료 기간, 동시 사용되는 약물을 비롯한 다양한 인자에 따라 조절될 수 있다. 성인의 경우, 상기 치료용 약학조성물을 1회 50ml~500ml의 양으로 체내에 투여 가능하며, 화합물일 경우 0.1ng/kg-10㎎/kg, 모노클로날 항체일 경우 0.1ng/kg-10㎎/kg의 용량으로 투여될 수 있다. 투여간격은 1일 1회 내지 12회일 수 있으며, 1일 12회 투여할 경우에는 2시간마다 1회씩 투여할 수 있다. 또한 본 발명의 약학조성물은 목적하고자 하는 치료를 위해 단독 또는 당업계에 공지된 다른 치료법, 예를 들어 화학요법제, 방사선 및 수술과 같이 투여될 수 있다. 또한 본 발명의 약학조성물은 면역 반응을 증진하기 위하여 고안된 다른 치료, 예를 들어 당업계에 주지된 것과 같은 어쥬번트 또는 사이토카인(또는 사이토카인을 코딩하는 핵산)과 혼합하여 투여될 수 있다. 바이오리스틱(biolistic) 전달 또는 생체 외(ex vivo) 처리와 같은 다른 표준 전달 방법들이 사용될 수도 있다. 생체 외 처리에서 예를 들어 항원제시 세포들(APCs), 수지상세포들, 말초혈액 단핵구 세포들, 또는 골수세포들을 환자 또는 적당한 공여자로부터 얻어서 본 약학조성물로 생체 외에서 활성화된 후 그 환자에게 투여될 수 있다.In one embodiment of the present invention, "administration" means introducing the composition of the present invention to a patient by any suitable method, and the administration route of the composition of the present invention is through any general route as long as it can reach the target tissue. can be administered. Specifically, oral administration, intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, intranasal administration, intrapulmonary administration, intrarectal administration, intracavitary administration, intraperitoneal administration, intrathecal administration, or intraocular administration It may be made in the form, and the intraocular administration is more specifically intravitreal injection, retrobulbar injection, subconjunctival injection, sub-tenon injection, or It may be made in the form of intraocular drops, but is not limited thereto. In the present invention, the effective amount is the type of disease, the severity of the disease, the type and amount of the active ingredient and other ingredients contained in the composition, the type of formulation and the patient's age, weight, general health condition, sex and diet, administration time, administration route And it can be adjusted according to various factors including the secretion rate of the composition, the treatment period, and drugs used simultaneously. In the case of adults, the therapeutic pharmaceutical composition can be administered to the body in an amount of 50 ml to 500 ml once, and in the case of a compound, 0.1 ng/kg-10 mg/kg, and in the case of a monoclonal antibody, 0.1 ng/kg-10 mg /kg may be administered. The administration interval may be 1 to 12 times a day, and in the case of administration 12 times a day, it may be administered once every 2 hours. In addition, the pharmaceutical composition of the present invention can be administered alone or with other treatments known in the art for the desired treatment, such as chemotherapy, radiation, and surgery. In addition, the pharmaceutical composition of the present invention may be administered in combination with other therapies designed to enhance the immune response, such as adjuvants or cytokines (or nucleic acids encoding cytokines) well known in the art. Other standard delivery methods may also be used, such as biolistic delivery or ex vivo treatment. In ex vivo treatment, for example, antigen presenting cells (APCs), dendritic cells, peripheral blood mononuclear cells, or bone marrow cells may be obtained from a patient or a suitable donor, activated in vitro with the present pharmaceutical composition, and then administered to the patient. have.
본 발명의 일 구체예에서 “식품 조성물”이란, 본 발명에서 목적으로 하는 적응증의 예방 또는 개선을 위해 다양하게 이용되는 것으로서, 본 발명의 조성물을 유효성분으로 포함하는 식품조성물은 각종 식품류, 예를 들어, 음료, 껌, 차, 비타민 복합제, 분말, 과립, 정제, 캡슐, 과자, 떡, 빵 등의 형태로 제조될 수 있다. 본 발명의 식품조성물은 독성 및 부작용이 거의 없는 기존의 식품용 섭취물로부터 개량되어 구성된 것이므로 예방 목적으로 장기간 복용 시에도 안심하고 사용할 수 있다. 본 발명의 조성물이 식품조성물에 포함될 때 그 양은 전체 중량의 0.1 내지 100%의 비율로 첨가할 수 있다. 여기서, 상기 식품조성물이 음료 형태로 제조되는 경우 지시된 비율로 상기 식품조성물을 함유하는 것 외에 특별한 제한점은 없으며 통상의 음료와 같이 여러가지 향미제 또는 천연탄수화물 등을 추가 성분으로서 함유할 수 있다. 즉, 천연탄수화물로서 포도당 등의 모노사카라이드, 과당 등의 디사카라이드, 슈크로스 등의 및 폴리사카라이드, 덱스트린, 시클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜 등을 포함할 수 있다. 상기 향미제로서는 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진등) 및 합성 향미제(사카린, 아스파르탐 등) 등을 들 수 있다. 그 외 본 발명의 식품조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성풍미제 및 천연풍미제 등의 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 통상적으로 본 발명의 조성물 100 중량부 당 0.1 내지 100 중량부의 범위에서 선택되는 것이 일반적이나, 이에 제한되는 것은 아니다.In one embodiment of the present invention, "food composition" is used in various ways to prevent or improve the indications aimed at in the present invention, and the food composition containing the composition of the present invention as an active ingredient is various foods, such as For example, it can be manufactured in the form of beverages, gum, tea, vitamin complexes, powders, granules, tablets, capsules, confectionery, rice cakes, and bread. Since the food composition of the present invention is improved from existing food intakes with little toxicity and side effects, it can be safely used even when taken for a long period of time for preventive purposes. When the composition of the present invention is included in a food composition, the amount may be added in an amount of 0.1 to 100% of the total weight. Here, when the food composition is prepared in the form of a beverage, there is no particular limitation except that the food composition is contained in the indicated ratio, and various flavors or natural carbohydrates may be included as additional ingredients as in conventional beverages. In other words, natural carbohydrates include monosaccharides such as glucose, disaccharides such as fructose, polysaccharides such as sucrose, and common sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. can do. Examples of the flavoring agent include natural flavoring agents (thaumatin, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.). Others of the present invention The food composition of is various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, Stabilizers, preservatives, glycerin, alcohol, carbonation agents used in carbonated beverages, etc. These components may be used independently or in combination The ratio of these additives is usually per 100 parts by weight of the composition of the present invention It is generally selected from the range of 0.1 to 100 parts by weight, but is not limited thereto.
본 발명의 일 구체예에서, 니코틴아마이드(nicotinamide), 또는 이의 유도체를 유효성분으로 포함하는 노인성 황반변성의 예방 또는 치료용 약학조성물을 제공하고, 상기 노인성 황반변성은 건성, 또는 습성인 것인 노인성 황반변성의 예방 또는 치료용 약학조성물을 제공하며, 상기 노인성 황반변성은 드루젠(drusen), 색소이상(pigmentary abnormality), 또는 망막상피의 위축(atrophy)을 동반하는 것인 노인성 황반변성의 예방 또는 치료용 약학조성물을 제공하며, 상기 위축은 지도형 위축(geographic atrophy)인 것인 노인성 황반변성의 예방 또는 치료용 약학조성물을 제공한다.In one embodiment of the present invention, there is provided a pharmaceutical composition for preventing or treating age-related macular degeneration comprising nicotinamide or a derivative thereof as an active ingredient, wherein the age-related macular degeneration is dry or wet, age-related macular degeneration Provides a pharmaceutical composition for prevention or treatment, wherein the age-related macular degeneration is accompanied by drusen, pigmentary abnormality, or atrophy of the retinal epithelium. It provides, and the atrophy provides a pharmaceutical composition for preventing or treating age-related macular degeneration, which is a geographic atrophy.
상기 니코틴아마이드는 하기 화학식 1로 표시되는 것이며, 상기 니코틴아마이드 유도체는 하기 화학식 2 또는 화학식 3으로 표시되는 것이다.The nicotinamide is represented by Formula 1 below, and the nicotinamide derivative is represented by Formula 2 or Formula 3 below.
[화학식 1][Formula 1]
[화학식 2] [Formula 2]
[화학식 3] [Formula 3]
본 발명의 다른 구체예에서, 니코틴아마이드(nicotinamide), 또는 이의 유도체를 유효성분으로 포함하는 노인성 황반변성의 예방 또는 개선용 식품조성물을 제공하고, 상기 노인성 황반변성은 건성, 또는 습성인 것인 노인성 황반변성의 예방 또는 개선용 식품조성물을 제공하며, 상기 노인성 황반변성은 드루젠(drusen), 색소이상(pigmentary abnormality), 또는 망막상피의 위축(atrophy)을 동반하는 것인 노인성 황반변성의 예방 또는 개선용 식품조성물을 제공하며, 상기 위축은 지도형 위축(geographic atrophy)인 것인 노인성 황반변성의 예방 또는 개선용 식품조성물을 제공한다.In another embodiment of the present invention, to provide a food composition for preventing or improving age-related macular degeneration comprising nicotinamide or a derivative thereof as an active ingredient, wherein the age-related macular degeneration is dry or wet Provides a food composition for prevention or improvement, wherein the age-related macular degeneration is accompanied by drusen, pigmentary abnormality, or atrophy of the retinal epithelium. A food composition for preventing or improving age-related macular degeneration It provides, and the atrophy provides a food composition for preventing or improving age-related macular degeneration, which is a geographic atrophy.
상기 니코틴아마이드는 하기 화학식 1로 표시되는 것이며, 상기 니코틴아마이드 유도체는 하기 화학식 2 또는 화학식 3으로 표시되는 것이다.The nicotinamide is represented by Formula 1 below, and the nicotinamide derivative is represented by Formula 2 or Formula 3 below.
[화학식 1][Formula 1]
[화학식 2] [Formula 2]
[화학식 3] [Formula 3]
이하 상기 본 발명을 단계별로 상세히 설명한다.Hereinafter, the present invention will be described in detail step by step.
본 발명에 따른 니코틴아마이드(nicotinamide), 또는 이의 유도체를 유효성분으로 포함하는 약학조성물 및 식품 조성물은 노인성 황반변성에서 망막상피세포의 퇴화를 구조적, 기능적으로 현저하게 회복시키는 효과가 있다.A pharmaceutical composition and a food composition containing nicotinamide or a derivative thereof according to the present invention as an active ingredient have an effect of significantly recovering structurally and functionally the degeneration of retinal epithelial cells in age-related macular degeneration.
도 1은 본 발명의 일 실시예에 따른, 렌티바이러스를 이용하는 방법으로 제조한 노인성 황반변성 동물모델이 목적과 같이 제조되었는지 확인한 결과이다.1 is a result of confirming whether an age-related macular degeneration animal model prepared by a method using a lentivirus according to an embodiment of the present invention was prepared as intended.
도 2는 본 발명의 일 실시예에 따른, 렌티바이러스를 이용하여 제조한 노인성 황반변성 동물모델에서 투여한 후보물질에 따른 노인성 황반변성 치료 효과를 망막상피세포에서 구조적으로 확인한 결과이다.2 is a result of structurally confirming the treatment effect of age-related macular degeneration in retinal epithelial cells according to the candidate substance administered in an age-related macular degeneration animal model prepared using a lentivirus according to an embodiment of the present invention.
도 3은 본 발명의 일 실시예에 따른, 요오드산 나트륨을 이용하여 제조한 노인성 황반변성 동물모델에서 투여한 후보물질에 따른 노인성 황반변성 치료 효과를 망막상피세포에서 구조적으로 확인한 결과이다.3 is a result of structurally confirming the treatment effect of age-related macular degeneration in retinal epithelial cells according to the candidate substance administered to the age-related macular degeneration animal model prepared using sodium iodate according to an embodiment of the present invention.
도 4a 내지 도 4d는 본 발명의 일 실시예에 따른, 요오드산 나트륨을 이용하여 제조한 노인성 황반변성 동물모델에서 투여한 후보물질에 따른 노인성 황반변성 치료 효과를 망막상피세포에서 기능적으로 확인한 결과이다.4a to 4d are the results of functionally confirming the treatment effect of age-related macular degeneration in retinal epithelial cells according to the candidate substance administered in the age-related macular degeneration animal model prepared using sodium iodate according to an embodiment of the present invention. .
지도형 위축을 구현하는 노인성 황반변성 동물 모델을 제조하고, 노인성 황반변성 치료용 후보물질로서 표 1의 화합물을 투여하였다. 그 결과, 화합물을 투여하지 않은 대조군의 경우 전형적인 노인성 황반변성의 지도형 위축을 나타내었으나, 표 1의 화합물을 투여한 경우에는 화학식 2(NMN) ≥ 화학식 3(NR) > 화학식 1(NAM)의 순서로 망막상피세포 퇴화의 구조적 또는 기능적 회복이 현저한 것을 확인하였다.An age-related macular degeneration animal model realizing geographic atrophy was prepared, and the compounds of Table 1 were administered as candidates for treatment of age-related macular degeneration. As a result, the control group to which the compound was not administered showed geographic atrophy of typical age-related macular degeneration, but in the case of administration of the compound of Table 1, the order of Formula 2 (NMN) ≥ Formula 3 (NR) > Formula 1 (NAM) It was confirmed that structural or functional recovery of retinal epithelial cell degeneration was remarkable.
이하, 본 발명을 하기의 실시예에 의해 상세히 설명한다. 단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail by the following examples. However, the following examples are only to illustrate the present invention, and the content of the present invention is not limited by the following examples.
실시예Example
실시예 1. 노인성 황반변성 동물 모델의 제조 및 후보물질 투여Example 1. Preparation of age-related macular degeneration animal model and administration of candidate substances
노인성 황반변성 동물 모델은 종래 공지된 방법(Kaneko, H. et al. DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. Nature 471, 325-330, doi:10.1038/nature09830. 2011.)과 동일하게 수행하였다. 상기 방법은 망막색소상피(Retina pigment epithelium: RPE) 내에 축적된 Alu RNA에 의해 지도형 위축을 발생시키는 방법이다. 구체적으로, GFP(green fluorescence protein) 표지된 Alu RNA 발현 렌티바이러스 벡터(Alu RNA expressing lentival vector) 0.8 X 108 genome copy(GC)/㎕ 농도로 마이크로리터 주사기 (WPI, 10 microliter syringe)에 로딩하여 준비하고, 8-10 주령 C57BL/6 마우스를 마취하고, 0.5%의 페닐에프린(phenylephrine) 및 0.5%의 트로픽아마이드(tropicamide)로 동공을 산동시켰다. 이후, 마우스의 눈꺼풀을 열고, 눈을 돌출시키고, 각막 표면에 점탄성 용액을 1방울 적용시킨 이후, 망막을 시각화 하기 위해 각막의 표면에 작은 원형 커버 슬라이드를 놓았다. 30 게이지 주사바늘로 각막 주변(Limbus) 1mm 떨어진 위치에 작은 절개를 만들고, 절개를 통해, 마이크로리터 주사기의 33 게이지 매선용 바늘(Blunt needle)을 넣고, 저항이 느껴지는 지점(망막하 공간, subretinal space)까지 주사바늘을 접근시켰다. 불필요한 조직 손상을 방지하기 위해 조심스럽고 부드럽게 바이러스를 1 ㎕ 주입한 이후, 20-30초 기다리고, 천천히 마이크로리터 주사기 바늘을 철회하였다. 망막 출혈이 없고, 망막하 수포(bleb)가 잘 형성되었는지 확인한 후 안구 표면에 항생연고를 도포하였다. 모든 실험 과정에서, 마우스의 체온을 유지하기 위해 온열 패드 위에서 실험을 수행하였다. 2주 후, 마우스로부터 안구 시료를 수득하여 망막색소상피 전체 봉입 면역염색(RPE whole mount immunostatining)을 수행하였다. Age-related macular degeneration animal model is the same as the previously known method (Kaneko, H. et al. DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. Nature 471, 325-330, doi:10.1038/nature09830. 2011.) performed. This method is a method of generating geographic atrophy by Alu RNA accumulated in retinal pigment epithelium (RPE). Specifically, GFP (green fluorescence protein)-labeled Alu RNA expressing lentival vector (Alu RNA expressing lentival vector) was loaded into a microliter syringe (WPI, 10 microliter syringe) at a concentration of 0.8 X 10 8 genome copy (GC)/μl Prepared, 8-10 week old C57BL/6 mice were anesthetized and pupil dilated with 0.5% phenylephrine and 0.5% tropicamide. After that, the eyelids of the mouse were opened, the eyes were protruded, and a drop of the viscoelastic solution was applied to the surface of the cornea, and then a small circular cover slide was placed on the surface of the cornea to visualize the retina. A small incision is made with a 30 gauge injection needle at a location 1 mm away from the limbus, and a 33 gauge blunt needle of a microliter syringe is inserted through the incision, and a point where resistance is felt (subretinal space) ), the needle was approached. After injecting 1 μl of virus carefully and gently to avoid unnecessary tissue damage, wait 20-30 seconds and slowly withdraw the microliter syringe needle. After confirming that there was no retinal hemorrhage and that subretinal blisters were well formed, antibiotic ointment was applied to the ocular surface. In all experimental procedures, the experiments were performed on a heating pad to maintain the body temperature of the mice. After 2 weeks, eye samples were obtained from the mice and RPE whole mount immunostatining was performed.
한편, 바이러스를 이용한 방법 이외에 화학적 방법의 노인성 황반변성 동물 모델을 추가로 제조하였다. 이를 위해서 상기와 동일하게 8-10 주령 C57BL/6 마우스를 준비하고, 요오드산 나트륨(Sodium iodate, NAIO3)을 20mg/Kg 농도로 꼬리 정맥을 통해 혈관내 주사하였다. 6일 후에, 망막 전위도(Electroretinogram: ERG)를 시행하고, 마우스로부터 안구 시료를 수득하여 망막색소상피 전체 봉입 면역염색(RPE whole mount immunostatining)을 수행하였다.On the other hand, in addition to the method using a virus, an animal model for age-related macular degeneration using a chemical method was additionally prepared. To this end, 8-10 week-old C57BL/6 mice were prepared in the same manner as above, and sodium iodate (NAIO 3 ) was injected intravascularly through the tail vein at a concentration of 20 mg/Kg. After 6 days, an electroretinogram (ERG) was performed, and eye samples were obtained from mice, and RPE whole mount immunostatining was performed.
노인성 황반변성 치료용 후보물질은 하기 표 1의 화합물을 이용하였으며, 상기 두 종류의 동물 모델을 제조하기 위한 렌티바이러스 또는 요오드산 나트륨을 투여하기 3일 전부터 안구 시료를 수득하는 날까지 1000mg/Kg/day의 농도로 매일 복강내 주사(Intraperitoneal injection)하였다.Candidates for the treatment of age-related macular degeneration used the compounds in Table 1 below, and from 3 days before administration of lentivirus or sodium iodate for preparing the above two types of animal models to the day of obtaining eye samples, 1000 mg/Kg/ It was intraperitoneal injection every day at the concentration of day.
실시예 2. 망막상피세포 형태 확인을 통한 후보물질의 노인성 황반변성 치료 효과 확인Example 2. Confirmation of age-related macular degeneration treatment effect of candidate substance through confirmation of retinal epithelial cell morphology
망막상피세포 형태 확인을 위한 망막세포 염색은 하기의 순서로 진행하였다. 먼저, 수득한 안구 시료를 1% 파라포름알데하이드(paraformaldehyde)로 1시간 동안 고정하고, 근육(Muscle), 각막(Cornea), 수정체(Lens), 및 신경망막세포(Neural retina)를 제거한 후, Sclera/Choroid/RPE complex를 방사상(radial)으로 총 8개로 절편하였다. 각 절편 조직을 5%의 소혈청 알부민(bovine serum albumin), 2%의 NDS(normal donkey serum), 및 0.3%의 트리톤 X-100(Triton™ X-100)이 포함된 인산완충생리식염수 (Phosphate-buffered saline) 용액에서 1시간 동안 블럭(blocking)하고, 세척한 후, 4℃에서 항 ZO-1 항체로 오버나잇 반응시켰다(overnight incubation). 이후 3회 세척하고, 실온에서 2차 항체와 1시간 반응시킨 후, 다시 세척하고, 조직을 슬라이드에 도말한 후 봉입하였다. 이를 형광현미경으로 관찰하였다. Retinal cell staining for confirmation of retinal epithelial cell morphology was performed in the following order. First, the obtained eye sample was fixed with 1% paraformaldehyde for 1 hour, and after removing the muscle, cornea, lens, and neural retina, Sclera The /Choroid/RPE complex was radially sectioned into eight pieces. Each tissue section was prepared in Phosphate buffered saline containing 5% bovine serum albumin, 2% NDS (normal donkey serum), and 0.3% Triton™ X-100. -buffered saline) solution for 1 hour after blocking, washing, and overnight reaction with anti-ZO-1 antibody at 4°C (overnight incubation). Thereafter, the cells were washed three times, reacted with the secondary antibody at room temperature for 1 hour, washed again, and the tissues were smeared on slides and then embedded. This was observed with a fluorescence microscope.
동물모델이 렌티바이러스를 이용한 모델인 경우에는 세포퇴화 면적/GFP 발현 면적(Transduction area)으로 비교하였으며, 동물모델이 요오드산 나트륨을 이용한 모델인 경우에는 세포퇴화 면적/전체 망막상피세포 면적으로 비교하였다.When the animal model was a model using lentivirus, cell degeneration area/GFP expression area (transduction area) was compared, and when the animal model was a model using sodium iodate, cell degeneration area/total retinal epithelial cell area were compared. .
실시예 2-1. 렌티바이러스를 이용한 동물 모델에서의 효과 확인Example 2-1. Confirmation of effect in animal models using lentivirus
먼저, 상기 실시예 1에서 렌티바이러스를 이용하는 방법으로 제조한 노인성 황반변성 동물모델이 목적과 같이 제조되었는지 확인한 결과를 도 1에 나타내었다. 도 1에서, 대조군으로서 GFP를 발현하는 렌티바이러스를 형질도입 하였을 때에는 정상 망막상피세포에서 구조적 변화가 발생하지 않았으나(좌측), Alu RNA를 발현하는 렌티바이러스를 형질도입 하였을 때에는 망막상피세포가 세포퇴화되어 망막상피세포의 크기가 커지고, 모양이 불규칙해진 것으로 나타났다(우측). 이를 통해 렌티바이러스를 이용하는 방법으로 목적하는 노인성 황반변성 동물모델이 잘 제조되었음을 확인할 수 있었다.First, the result of confirming whether the age-related macular degeneration animal model prepared by the method using the lentivirus in Example 1 was prepared as intended is shown in FIG. 1. In Figure 1, when transduction of lentivirus expressing GFP as a control, no structural change occurred in normal retinal epithelial cells (left), but when transduction of lentivirus expressing Alu RNA, retinal epithelial cells degenerated As a result, the retinal epithelial cells increased in size and became irregular in shape (right). Through this, it was confirmed that the target age-related macular degeneration animal model was well prepared by the method using the lentivirus.
렌티바이러스를 이용하여 제조한 노인성 황반변성 동물모델에서 투여한 후보물질에 따른 노인성 황반변성 치료 효과를 확인한 결과는 도 2에 나타내었다.The results of confirming the treatment effect of age-related macular degeneration according to the candidate substance administered in the age-related macular degeneration animal model prepared using lentivirus are shown in FIG. 2 .
실험 결과, 화합물을 투여하지 않은 대조군(Alu RNA)의 경우 전형적인 노인성 황반변성의 지도형 위축(geographic atrophy)을 나타내었다. 화학식 1을 투여(Alu RNA + NAM treatment)한 경우 망막상피세포의 크기 증가가 관찰되나, 대조군(Alu RNA)에 비하여는 망막상피세포의 크기가 확연히 작았다. 화학식 2를 투여(Alu RNA + NMN treatment)한 경우에는 망막상피세포의 퇴화가 관찰되지 않고, 정상 망막상피세포에 가까운 구조를 보였으며, 화학식 3을 투여(Alu RNA + NR treatment)한 경우에는 소수의 망막상피세포에서 약간의 크기 증가가 관찰되었으나, 전체적으로는 정상 망막상피세포에 가까운 구조를 보였다. 상기 결과로부터 렌티바이러스를 이용한 동물 모델에서 망막상피세포 퇴화의 구조적 회복 정도는 화학식 2(NMN) > 화학식 3(NR) > 화학식 1(NAM)의 순서로 치료 효과가 현저한 것을 알 수 있었다.As a result of the experiment, the control group (Alu RNA) to which the compound was not administered showed typical geographic atrophy of age-related macular degeneration. When Formula 1 was administered (Alu RNA + NAM treatment), an increase in the size of retinal epithelial cells was observed, but the size of retinal epithelial cells was significantly smaller than that of the control group (Alu RNA). When Formula 2 was administered (Alu RNA + NMN treatment), retinal epithelial cell degeneration was not observed, and a structure close to normal retinal epithelial cells was shown, and when Formula 3 was administered (Alu RNA + NR treatment), a small number of Although a slight increase in size was observed in the retinal epithelial cells of , the overall structure was close to that of normal retinal epithelial cells. From the above results, it was found that the degree of structural recovery of degeneration of retinal epithelial cells in an animal model using lentivirus was in the order of Chemical Formula 2 (NMN) > Chemical Formula 3 (NR) > Chemical Formula 1 (NAM), and the therapeutic effect was remarkable.
실시예 2-2. 요오드산 나트륨을 이용한 동물 모델에서의 효과 확인Example 2-2. Confirmation of effect in animal models using sodium iodate
상기 실시예 1에서 요오드산 나트륨을 이용하는 방법으로 제조한 노인성 황반변성 동물모델에서 투여한 후보물질에 따른 노인성 황반변성 치료 효과를 확인한 결과는 도 3에 나타내었다.The result of confirming the treatment effect of age-related macular degeneration according to the candidate substance administered in the age-related macular degeneration animal model prepared by the method using sodium iodate in Example 1 is shown in FIG. 3 .
실험결과, 화합물을 투여하지 않은 대조군(NaIO3)의 경우 망막상피세포의 형체를 알아보기 어려울 정도로 세포 퇴화가 일어난 반면에, 화학식 1을 투여(NaIO3 + NAM treatment)한 경우 망막상피세포의 형태는 회복되었으나, 망막상피세포 크기가 정상보다는 큰 것으로 나타났다. 화학식 2를 투여(NaIO3 + NMN treatment)하거나, 화학식 3을 투여(NaIO3 + NR treatment)한 경우에는 망막상피세포의 퇴화가 관찰되지 않고, 정상 망막상피세포에 가까운 구조를 보였다. 상기 결과로부터 요오드산 나트륨을 이용한 동물 모델에서 망막상피세포 퇴화의 구조적 회복 정도는 화학식 2(NMN) = 화학식 3(NR) > 화학식 1(NAM)의 순서로 치료 효과가 현저한 것을 알 수 있었다.As a result of the experiment, in the case of the control group (NaIO 3 ) not administered with the compound, cell degeneration occurred to the extent that it was difficult to recognize the shape of the retinal epithelial cells, whereas in the case of administration of Chemical Formula 1 (NaIO 3 + NAM treatment), the shape of the retinal epithelial cells was recovered, but the retinal epithelial cell size was larger than normal. When Formula 2 was administered (NaIO 3 + NMN treatment) or Formula 3 was administered (NaIO 3 + NR treatment), degeneration of retinal epithelial cells was not observed, and a structure close to normal retinal epithelial cells was shown. From the above results, it was found that the degree of structural recovery of degeneration of retinal epithelial cells in an animal model using sodium iodate was in the order of Chemical Formula 2 (NMN) = Chemical Formula 3 (NR) > Chemical Formula 1 (NAM), and the therapeutic effect was remarkable.
실시예 3. 객관시 시력 측정을 통한 후보물질의 노인성 황반변성 치료 효과 확인Example 3. Confirmation of age-related macular degeneration treatment effect of candidate substance through visual acuity measurement in objective view
요오드산 나트륨을 이용한 동물 모델의 경우, 모델링 6일 후에 망막 전위도(Electroretinogram: ERG) 검사를 수행하고, 그 결과를 도 4a 내지 도 4b에 나타내었다.In the case of an animal model using sodium iodate, an electroretinogram (ERG) test was performed 6 days after modeling, and the results are shown in FIGS. 4a to 4b.
실험결과, 화합물을 투여하지 않은 대조군(NaIO3)의 경우 B-wave amplitude는 20.44 μV 로 저하되어 있으나, 화학식 1을 투여(NaIO3 + NAM treatment)한 경우 B-wave amplitude는 44.64 μV 로 회복되었다. 또한 B-wave amplitude는 화학식 2를 투여(NaIO3 + NMN treatment)한 경우 87.17 μV 로, 화학식 3을 투여(NaIO3 + NR treatment)한 경우 59.87 μV 로 회복되어, 요오드산 나트륨을 이용한 동물 모델에서 약물에 의한 기능적 회복(객관적 시력 상승; ERG 상에서의 B-wave amplitude)은 화학식 2(NMN) > 화학식 3(NR) > 화학식 1(NAM)의 순서로 치료 효과가 현저한 것을 알 수 있었다.As a result of the experiment, in the case of the control group (NaIO3) not administered with the compound, the B-wave amplitude was reduced to 20.44 μV, but when Formula 1 was administered (NaIO3 + NAM treatment), the B-wave amplitude was recovered to 44.64 μV. In addition, the B-wave amplitude recovered to 87.17 μV when Chemical Formula 2 was administered (NaIO3 + NMN treatment) and to 59.87 μV when Chemical Formula 3 was administered (NaIO3 + NR treatment), indicating that the drug in an animal model using sodium iodate Functional recovery (objective visual acuity increase; B-wave amplitude on ERG) was found to be significant in the order of Formula 2 (NMN) > Formula 3 (NR) > Formula 1 (NAM).
상기 실시예 1 내지 3의 결과로부터, 니코틴아마이드(nicotinamide), 또는 이의 유도체가 노인성 황반변성의 예방 또는 치료에 현저한 효과가 있음을 알 수 있었다.From the results of Examples 1 to 3, it can be seen that nicotinamide or a derivative thereof has a remarkable effect on preventing or treating age-related macular degeneration.
이상에서 본 발명에 대하여 상세하게 설명하였지만 본 발명의 권리범위는 이에 한정되는 것은 아니고, 청구범위에 기재된 본 발명의 기술적 사상을 벗어나지 않는 범위 내에서 다양한 수정 및 변형이 가능하다는 것은 당 기술분야의 통상의 지식을 가진 자에게는 자명할 것이다.Although the present invention has been described in detail above, the scope of the present invention is not limited thereto, and various modifications and variations are possible without departing from the technical spirit of the present invention described in the claims. It will be self-evident to those who have knowledge of
본 발명은 노인성 황반변성의 예방 또는 치료를 위한 약학 조성물에 관한 것이다.The present invention relates to a pharmaceutical composition for preventing or treating age-related macular degeneration.
노인성 황반변성(age-related macular degeneration: AMD)은 나이가 들면서 망막의 황반부에 여러 가지 변화가 동반되어 생기는 질병이다. 나이가 증가함에 따라 발생율이 증가하며, 선진국에서는 성인 실명 원인 1위 질환으로 전세계적으로 약 2억명 정도의 환자가 있는 것으로 알려져 있다. 그러나 AMD의 대부분을 차지하는 건성 중 진행성 황반변성을 지도형 위축(geographic atrophy: GA)라고 하는데, 현재로서는 치료법이 전무하여 노인성 황반변성의 최대 난제인 실정이다.Age-related macular degeneration (AMD) is a disease caused by various changes in the macular area of the retina with aging. The incidence increases with age, and it is known that there are about 200 million patients worldwide as the number one cause of adult blindness in developed countries. However, progressive macular degeneration, which accounts for most of AMD, is called geographic atrophy (GA), and currently there is no treatment, which is the biggest challenge in age-related macular degeneration.
본 발명의 약학조성물은 습성뿐만 아니라 치료법이 전무한 건성의 노인성 황반변성에서도 매우 현저한 치료 효과를 발휘하였으므로, 의료 분야에서 크게 이용될 수 있을 것으로 기대된다.The pharmaceutical composition of the present invention is expected to be widely used in the medical field because it exhibited a very remarkable therapeutic effect not only in wet but also in dry age-related macular degeneration for which there is no treatment.
Claims (14)
- 니코틴아마이드(nicotinamide), 또는 이의 유도체를 유효성분으로 포함하는 노인성 황반변성의 예방 또는 치료용 약학조성물.A pharmaceutical composition for preventing or treating age-related macular degeneration comprising nicotinamide or a derivative thereof as an active ingredient.
- 제 1항에 있어서,According to claim 1,상기 니코틴아마이드는 하기 화학식 1로 표시되는 것인, 약학조성물.The pharmaceutical composition, wherein the nicotinamide is represented by Formula 1 below.[화학식 1] [Formula 1]
- 제 1항에 있어서,According to claim 1,상기 니코틴아마이드 유도체는 하기 화학식 2 또는 화학식 3으로 표시되는 것인, 약학조성물.The nicotinamide derivative is a pharmaceutical composition represented by Formula 2 or Formula 3 below.[화학식 2] [Formula 2]
[화학식 3] [Formula 3]
- 제 1항에 있어서,According to claim 1,상기 노인성 황반변성은 건성, 또는 습성인 것인, 약학조성물.The age-related macular degeneration is dry, or wet, the pharmaceutical composition.
- 제 1항에 있어서,According to claim 1,상기 노인성 황반변성은 드루젠(drusen), 색소이상(pigmentary abnormality), 또는 망막상피의 위축(atrophy)을 동반하는 것인, 약학조성물.The age-related macular degeneration is accompanied by drusen, pigmentary abnormality, or atrophy of the retinal epithelium, the pharmaceutical composition.
- 제 5항에 있어서,According to claim 5,상기 위축은 지도형 위축(geographic atrophy)인 것인, 약학조성물.Wherein the atrophy is geographic atrophy (geographic atrophy), the pharmaceutical composition.
- 니코틴아마이드(nicotinamide), 또는 이의 유도체를 유효성분으로 포함하는 노인성 황반변성의 예방 또는 개선용 식품조성물.Nicotinamide (nicotinamide), or a food composition for preventing or improving age-related macular degeneration containing a derivative thereof as an active ingredient.
- 제 7항에 있어서,According to claim 7,상기 니코틴아마이드는 하기 화학식 1로 표시되는 것인, 식품조성물.The nicotinamide is a food composition represented by Formula 1 below.[화학식 1] [Formula 1]
- 제 7항에 있어서,According to claim 7,상기 니코틴아마이드 유도체는 하기 화학식 2 또는 화학식 3으로 표시되는 것인, 식품조성물.The nicotinamide derivative is a food composition represented by Formula 2 or Formula 3 below.[화학식 2] [Formula 2]
[화학식 3] [Formula 3]
- 제 7항에 있어서,According to claim 7,상기 노인성 황반변성은 건성, 또는 습성인 것인, 식품조성물.The age-related macular degeneration is dry, or wet, food composition.
- 제 7항에 있어서,According to claim 7,상기 노인성 황반변성은 드루젠(drusen), 색소이상(pigmentary abnormality), 또는 망막상피의 위축(atrophy)을 동반하는 것인, 식품조성물.Wherein the age-related macular degeneration is accompanied by drusen, pigmentary abnormality, or atrophy of the retinal epithelium.
- 제 11항에 있어서,According to claim 11,상기 위축은 지도형 위축(geographic atrophy)인 것인, 식품조성물.The food composition, wherein the atrophy is a geographic atrophy.
- 개체에게, 니코틴아마이드(nicotinamide), 또는 이의 유도체를 유효성분으로 포함하는 약학조성물을 투여하는 단계를 포함하는, 노인성 황반변성의 예방 또는 치료 방법.A method for preventing or treating age-related macular degeneration, comprising administering to a subject a pharmaceutical composition containing nicotinamide or a derivative thereof as an active ingredient.
- 니코틴아마이드(nicotinamide), 또는 이의 유도체의 노인성 황반변성의 예방 또는 치료 용도.Use of nicotinamide or a derivative thereof for prevention or treatment of age-related macular degeneration.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210060802A KR102633321B1 (en) | 2021-05-11 | 2021-05-11 | Pharmarceutical composition for preventing or treating of age-related macular degeneration |
| KR10-2021-0060802 | 2021-05-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2022240165A1 true WO2022240165A1 (en) | 2022-11-17 |
Family
ID=84028669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2022/006706 WO2022240165A1 (en) | 2021-05-11 | 2022-05-11 | Pharmaceutical composition for preventing or treating age-related macular degeneration |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR102633321B1 (en) |
| WO (1) | WO2022240165A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170058976A (en) * | 2014-09-17 | 2017-05-29 | 팬옵티카, 인크. | Ocular formulations for drug-delivery and protection of the anterior segment of the eye |
| KR20170120583A (en) * | 2014-12-30 | 2017-10-31 | 셀 큐어 뉴로사이언시스 리미티드 | Treatment of retinal diseases |
| KR20180039658A (en) * | 2015-08-05 | 2018-04-18 | 메트로 인터내셔널 바이오테크 엘엘씨 | Nicotinamide mononucleotide derivatives and uses thereof |
-
2021
- 2021-05-11 KR KR1020210060802A patent/KR102633321B1/en active IP Right Grant
-
2022
- 2022-05-11 WO PCT/KR2022/006706 patent/WO2022240165A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170058976A (en) * | 2014-09-17 | 2017-05-29 | 팬옵티카, 인크. | Ocular formulations for drug-delivery and protection of the anterior segment of the eye |
| KR20170120583A (en) * | 2014-12-30 | 2017-10-31 | 셀 큐어 뉴로사이언시스 리미티드 | Treatment of retinal diseases |
| KR20180039658A (en) * | 2015-08-05 | 2018-04-18 | 메트로 인터내셔널 바이오테크 엘엘씨 | Nicotinamide mononucleotide derivatives and uses thereof |
Non-Patent Citations (2)
| Title |
|---|
| EBELING MARA C., POLANCO JORGE R., QU JUN, TU CHENGJIAN, MONTEZUMA SANDRA R., FERRINGTON DEBORAH A.: "Improving retinal mitochondrial function as a treatment for age-related macular degeneration", REDOX BIOLOGY, vol. 34, 1 July 2020 (2020-07-01), NL , pages 1 - 13, XP093004003, ISSN: 2213-2317, DOI: 10.1016/j.redox.2020.101552 * |
| SAINI JANMEET S.; CORNEO BARBARA; MILLER JUSTINE D.; KIEHL THOMAS R.; WANG QINGJIE; BOLES NATHAN C.; BLENKINSOP TIMOTHY A.; STERN : "Nicotinamide Ameliorates Disease Phenotypes in a Human iPSC Model of Age-Related Macular Degeneration", CELL STEM CELL, vol. 20, no. 5, 4 May 2017 (2017-05-04), AMSTERDAM, NL , pages 1 - 20, XP085000091, ISSN: 1934-5909, DOI: 10.1016/j.stem.2016.12.015 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220153343A (en) | 2022-11-18 |
| KR102633321B1 (en) | 2024-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201038544A (en) | Anti-neurodegenerative diseases agents | |
| JP6874075B2 (en) | Taiwan Propolis Extract for Treating Eye Diseases | |
| WO2022240165A1 (en) | Pharmaceutical composition for preventing or treating age-related macular degeneration | |
| CN102218051A (en) | Application of sodium valproate in preparation of medicament for treating or improving optic nerve pathological changes of glaucoma | |
| KR20100124756A (en) | Prophylactic or therapeutic agent for ocular disease accompanied by optic nerve disorder | |
| US10967029B2 (en) | Method of using Cistanche tubulosa extract to prevent, slow down, or treat an eye disease caused by oxidative stress | |
| WO2013191401A1 (en) | Composition for treating or preventing diseases caused by vascular permeability, containing imatinib or pharmaceutically acceptable salt thereof as active ingredient | |
| KR20040014600A (en) | OPTIC NERVE PROTECTING AGENTS CONTAINING α1 RECEPTOR BLOCKER AS THE ACTIVE INGREDIENT | |
| CN114533818A (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating retinitis pigmentosa | |
| CN111662349B (en) | Flos Buddlejae extract, and preparation method and application thereof | |
| Erringer et al. | Chloroquine neuromyopathy associated with keratopathy and retinopathy. | |
| EP1859795A1 (en) | Therapeutic agent for ophthalmic disease | |
| CN108653306B (en) | Application of goldfish grass extract-6-neohesperidoside in treatment of senile dementia | |
| CN106822152B (en) | Pharmaceutical composition and application thereof | |
| CN116139212B (en) | Ocular hypotensive pharmaceutical composition, preparation method and application thereof | |
| WO2023033483A1 (en) | Pharmaceutical composition for preventing or treating diabetic eye disease comprising sglt-2 inhibitor | |
| WO2022235023A1 (en) | Pharmaceutical composition for prevention or treatment of ischemic brain disease | |
| US11369649B1 (en) | Composition for prevention or treatment of ocular diseases comprising extracellular vesicles derived from lactobacillus paracasei | |
| WO2022035169A1 (en) | Composition for prevention and treatment of myopathy | |
| CA2451475A1 (en) | Agent for protection of retinal neurons | |
| US20090022757A1 (en) | Method for treating photoreceptor cell degeneration | |
| CN110755621B (en) | Composition containing Senp expression regulating reagent and application of composition in preparation of anti-hepatic fibrosis medicine | |
| KR102068697B1 (en) | Composition for Preventing or Treating Inflammatory Ocular Surface Disease | |
| KR100653557B1 (en) | Composition for preventing or treating cataract | |
| US20080318939A1 (en) | Methods for treating ophthalmic disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22807812 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 22807812 Country of ref document: EP Kind code of ref document: A1 |